AR066108A1 - Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson - Google Patents

Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson

Info

Publication number
AR066108A1
AR066108A1 ARP080101602A ARP080101602A AR066108A1 AR 066108 A1 AR066108 A1 AR 066108A1 AR P080101602 A ARP080101602 A AR P080101602A AR P080101602 A ARP080101602 A AR P080101602A AR 066108 A1 AR066108 A1 AR 066108A1
Authority
AR
Argentina
Prior art keywords
piridin
oxido
carboxamide
parkinson
disease
Prior art date
Application number
ARP080101602A
Other languages
English (en)
Spanish (es)
Inventor
Claire Dolgorge
Gilles Poughon
Philippe Delay-Goyet
Christine Ravinet-Trillou
Christine Menet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR066108A1 publication Critical patent/AR066108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP080101602A 2007-04-19 2008-04-18 Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson AR066108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
AR066108A1 true AR066108A1 (es) 2009-07-22

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101602A AR066108A1 (es) 2007-04-19 2008-04-18 Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935219A1 (en) * 2012-11-28 2015-10-28 Sanofi METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
UY31035A1 (es) 2008-11-28
KR20150004885A (ko) 2015-01-13
MY148092A (en) 2013-02-28
EA200970970A1 (ru) 2010-02-26
AU2008257322A1 (en) 2008-12-04
NZ580482A (en) 2011-10-28
MX2009011284A (es) 2009-11-02
EP2146714B1 (fr) 2011-06-22
SI2146714T1 (sl) 2011-10-28
JP2010524906A (ja) 2010-07-22
KR101503942B1 (ko) 2015-03-18
AU2008257322B2 (en) 2013-06-13
ES2367408T3 (es) 2011-11-03
PL2146714T3 (pl) 2011-10-31
EA019194B1 (ru) 2014-01-30
TW200911247A (en) 2009-03-16
US20100130554A1 (en) 2010-05-27
IL201448A (en) 2014-08-31
EP2146714A1 (fr) 2010-01-27
IL201448A0 (en) 2010-05-31
KR20090130059A (ko) 2009-12-17
PA8776801A1 (es) 2008-11-19
PT2146714E (pt) 2011-09-02
HRP20110666T1 (hr) 2011-10-31
CL2008001136A1 (es) 2009-01-16
DK2146714T3 (da) 2011-10-10
CY1111840T1 (el) 2015-10-07
ATE513548T1 (de) 2011-07-15
JO2678B1 (en) 2013-03-03
CA2684174C (fr) 2014-02-25
HK1141725A1 (en) 2010-11-19
ME00935B (me) 2012-06-20
WO2008145841A1 (fr) 2008-12-04
MA31367B1 (fr) 2010-05-03
BRPI0810444A2 (pt) 2016-05-31
FR2915100B1 (fr) 2009-06-05
ZA200907251B (en) 2011-04-28
CA2684174A1 (fr) 2008-12-04
RS51869B (sr) 2012-02-29
FR2915100A1 (fr) 2008-10-24
JP5386478B2 (ja) 2014-01-15
TWI439269B (zh) 2014-06-01
CN101663035A (zh) 2010-03-03
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
ECSP099806A (es) Oxazolidinonas sustituidas y su uso
DOP2009000207A (es) Nueva forma de dosificación
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
ES2531516T3 (es) Uso de escina
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
AR066108A1 (es) Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
PY08013253A (es) Utilización de 4-ciclopropilmetoxi-N-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la médula espinal.
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
PA8776701A1 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure